News
2 minute read

MBHB Partner Kevin Noonan Quoted in Law360.com Article Entitled, "High Court Biosimilar Drama Intact After Amgen-Apotex Denial"

Kevin E. Noonan, Ph.D.December 12, 2016

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a December 12, 2016 edition of Law360.com in an article entitled, “High Court Biosimilar Drama Intact After Amgen-Apotex Denial.” The U.S. Supreme Court’s refusal Monday to review a major biosimilar ruling involving Amgen and Apotex doesn’t necessarily mean that justices agree with the ruling, according to attorneys who predict that justices may use a separate case to tackle the same question about notice of biosimilar sales. View the article